[1] Sarin SK, Mishra SR. Endoscopic therapy for gastric varices. Clin Liver Dis, 2010, 14(2): 263-279. [2] Bazarbashi AN, Ryou M. Gastric variceal bleeding. Curr Opin Gastroenterol, 2019, 35(6): 524-534. [3] Wani ZA, Bhat RA, Bhadoria AS, et al. Gastric varices: classification, endoscopic and ultrasonographic management. J Res Med Sci, 2015, 20(12): 1200-1207. [4] Goral V, Yilmaz N. Current approaches to the treatment of gastric varices: glue, coil application, TIPS, and BRTO. Medicina (Kaunas), 2019, 55(7):335-343. [5] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology, 2017, 65(1): 310-335. [6] Kanagawa H, Mima S, Kouyama H, et al. A successfully treated case of fundic varices by retrograde transvenous obliteration with balloon. Nihon Shokakibyo Gakkai Zasshi, 1991, 88(7): 1459-1462. [7] Hong CH, Kim HJ, Park JH, et al. Treatment of patients with gastric variceal hemorrhage: endoscopic N-butyl-2-cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol, 2009, 24(3): 372-378. [8] Yoon CJ, Chung JW, Park JH. Transjugular intrahepatic portosystemic shunt for acute variceal bleeding in patients with viral liver cirrhosis: predictors of early mortality. Am J Roentgenol, 2005, 185(4): 885-889. [9] Van Buuren HR, Ter Borg PC. Transjugular intrahepatic portosystemic shunt (TIPS): indications and long-term patency. Scand J Gastroenterol Suppl, 2003, 5(239): 100-104. [10] Somberg KA. TIPS: safe, effective, better? Am J Gastroenterol, 1997, 92(9): 1412-1416. [11] Kerlan RJ, Laberge JM, Baker EL, et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol, 1995, 6(6): 917-921. [12] Simon-Talero M, Roccarina D, Martinez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology, 2018, 154(6): 1694-1705. [13] Leng X, Zhang F, Zhang M, et al. Comparison of transjugular intrahepatic portosystemic shunt for treatment of variceal bleeding in patients with cirrhosis with or without spontaneous portosystemic shunt. Eur J Gastroenterol Hepatol, 2019, 31(7): 853-858. [14] Chikamori F, Kuniyoshi N, Shibuya S, et al. Correlation between endoscopic and angiographic findings in patients with esophageal and isolated gastric varices. Dig Surg, 2001, 18(3): 176-181. [15] Yu Q, Liu C, Raissi D. Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for gastric varices: a meta-analysis. J Clin Gastroenterol, 2019, 2(1):112-124. [16] Ninoi T, Nishida N, Kaminou T, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. Am J Roentgenol, 2005, 184(4): 1340-1346. [17] Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol, 2001, 12(3): 327-336. [18] Nakai M, Sato M, Sahara S, et al. Transhepatic catheter-directed thrombolysis for portal vein thrombosis after partial splenic embolization in combination with balloon-occluded retrograde transvenous obliteration of splenorenal shunt. World J Gastroenterol, 2006, 12(31): 5071-5074. [19] Toyonaga A, Oho K. Should B-RTO be the first-line treatment for portosystemic encephalopathy? Intern Med, 2001, 40(8): 677-678. [20] Mukund A, Rajesh S, Arora A, et al. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol, 2012, 23(9): 1200-1206. [21] Baimakhanov Z, Soyama A, Takatsuki M, et al. Effective balloon-occluded retrograde transvenous obliteration of the superior mesenteric vein-inferior vena cava shunt in a patient with hepatic encephalopathy after living donor liver transplantation. Clin J Gastroenterol, 2014, 7(4): 342-345. [22] Lee E W, Lee A E, Saab S, et al. Retrograde transvenous obliteration (RTO): a new treatment option for hepatic encephalopathy. Dig Dis Sci, 2020, 2(2):176-187. |